An audit of patients with mature T cell non-Hodgkin’s lymphoma by transplant status in Tasmania — ASN Events
  1. Schedule
  2. Posters 2
  3. An audit of patients with mature T cell non-Hodgkin’s lymphoma by transplant status in Tasmania

An audit of patients with mature T cell non-Hodgkin’s lymphoma by transplant status in Tasmania (#354)

Ciara J Conduit 1 , Rosemary Harrup 1 , Scott Ragg 1 , Anna Johnston 1
  1. Department of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia

Aim
Gain an understanding of the outcomes of patients diagnosed with mature T cell non-Hodgkin’s lymphoma (NHL) in Tasmania.

Method
Retrospective analysis of medical records for patients identified via the Tasmanian Cancer Registry (TCR) with mature T cell NHL between 2003-2013.

Result
44 patients were diagnosed with T cell NHL statewide via TCR. Data was extracted from 29 records with 15 records yet to be analysed (will be performed prior to COSA ASM).

Of 29 patients, 22 (76%) were confirmed mature T cell NHL in medical records. Seven were diagnosed outside the study period (7%), or did not have T cell NHL (17%). 11 were male (50%) and the median age at diagnosis was 68 (range 30-85).

Ten patients received CHOP (45%), two CHEOP (9%), and three (14%) other induction chemotherapy. Three (14%) did not receive chemotherapy, due to advanced disease at diagnosis (9%) or other reasons (5%). 8 patients (36%) subsequently received autologous stem cell transplant (ASCT). There were no unexpected toxicities/mortality.

Median survival overall was 22 (range 0-98) months from diagnosis. Overall mortality was 64% during median follow-up of 22 months. Median survival of transplanted cohort was to 29 months (range 16-66); non-transplant 19 months (range 0-98). Four transplanted patients (50%) died during the study period; 10 (71%) not transplanted. The median age of those transplanted (62 years) was 11 years younger than those who were not.

Conclusion
There were a number of long-term survivors in both transplanted/non-transplanted groups although median survival was longer in the transplanted group. While there is a likelihood of selection bias given the younger age of those transplanted, our findings lend support to the role of high-dose chemotherapy with ASCT for eligible patients with mature T cell NHL given poor outcomes with conventional chemotherapy.

Given the paucity of demographic data surrounding rare malignancies such as T cell lymphoma, our data also raises concern regarding discrepancies between clinical records and the state cancer registry and has implications for future research. 

#COSA2015